We read with interest the study "Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals" by Dr Sánchez-Azofra and colleagues (1). The authors studied 506 hepatitis C virus (HCV) patients with sustained virological response (SVR) after direct-acting antivirals, all included patients had stage 3 fibrosis. Dr Sánchez-Azofra and colleagues found that the annual incidence of primary liver tumors in this cohort was 0.47%. Based on these findings, the authors concluded that the incidence of primary liver tumors among F3 fibrosis patients with HCV who had achieved SVR was lower than the 1.5% annual cut-off considered cost effective for hepatocellular carcinoma (HCC) surveillance (2). We congratulate the authors on studying this clinically relevant topic. However, we have several concerns regarding their conclusions.
View details for DOI 10.1111/liv.15072
View details for PubMedID 34587343